A011202 studies how to treat the axilla when sentinel nodes remain positive after chemotherapy. Both registry arms include radiation; this differs from the B-51 ypN0 question.
The retrieved registry describes an open-label randomised phase 3 comparison in cT1 to T3 N1 breast cancer with residual positive sentinel-node disease after neoadjuvant chemotherapy. The protocol requires a nodal metastasis greater than 0.2 millimetres; isolated tumour cells at or below that size are treated as N0i+. One arm includes completion level I/II axillary dissection and nodal radiation. The other includes radiation to the full axilla and nodal regions without that dissection.
The captured record lists 2,012 actual participants, active not recruiting status and estimated primary completion on 31 January 2031. Its primary measure is invasive breast cancer recurrence-free interval, with a stated follow-up timeframe up to eight years after radiation completion. The captured record supplies no efficacy estimate. Registry status is separate from a treatment result or availability at a local site.
Shares IMRT / IGRT (modern external beam), Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares the tags education-audit, local-treatment.
Shares Completion surgery, Sentinel lymph node biopsy, IMRT / IGRT (modern external beam), Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/